drugset / Trial / NCT05365438
Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Phase 4
Recruiting
105 enrolled
Seoul National University Bundang Hospital
Korea United Pharm. Inc. · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 20 mg | — |
| Comparator | Ezetimibe | Unknown | 10 mg | — |
| Comparator | Omega-3 fatty acids | Unknown | 2000 mg | — |